Validation and clinical application of transactivation assays forRUNX1variant classification
Open Access
- 27 May 2022
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (11) , 3195-3200
Abstract
Familial platelet disorder with associated myeloid malignancies (RUNX1-familial platelet disorder [RUNX1-FPD]) is caused by heterozygous pathogenic germline variants of RUNX1. In the present study, we evaluate the applicability of transactivation assays to investigate RUNX1 variants in different regions of the protein. We studied 11 variants to independently validate transactivation assays supporting variant classification following the ClinGen Myeloid Malignancies Variant Curation Expert Panel guidelines. Variant classification is key for the translation of genetic findings. We showed that new assays need to be developed to assess C-terminal RUNX1 variants. Two variants of uncertain significance (VUS) were reclassified to likely pathogenic. Additionally, our analyses supported the (likely) pathogenic classification of 2 other variants. We demonstrated functionality of 4 VUS, but reclassification to (likely) benign was challenging and suggested the need for reevaluating current classification guidelines. Finally, clinical utility of our assays was illustrated in the context of 7 families. Our data confirmed RUNX1-FPD suspicion in 3 families with RUNX1-FPD-specific family history, whereas for 3 variants identified in RUNX1-FPD-nonspecific families, no functional defect was detected. Applying functional assays to support RUNX1 variant classification can be essential for adequate care of index patients and their relatives at risk. It facilitates translation of genetic data into personalized medicine.Keywords
This publication has 22 references indexed in Scilit:
- Defective acid hydrolase secretion in RUNX1 haplodeficiency: Evidence for a global platelet secretory defectHaemophilia, 2017
- RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM)Seminars in Hematology, 2017
- Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disordersOrphanet Journal of Rare Diseases, 2016
- Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemiaLeukemia, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targetsJournal of Thrombosis and Haemostasis, 2014
- RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genesLeukemia, 2013
- RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesisFrontiers in Bioscience-Landmark, 2012
- Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancyBlood, 2008
- Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemiaNature Genetics, 1999